OncoSignal
Live from Open Targets Platform, fetched 2026-11-12 08:45 UTC. Every row links to its source record.

CDH11 cadherin 11

ENSG00000140937 · protein coding · Open Targets profile

Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. Required for proper focal adhesion assembly (PubMed:33811546). Involved in the regulation of cell migration (PubMed:33811546). .

In 14 of 15 cancers, the evidence for CDH11 comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751Elsahy-Waters syndromeElsahy-Waters syndromeElsahy-Waters syndrome: germline 0.77pancreatic ductal adenocarcinomapancreatic ductal adenocarcinomapancreatic ductal adenocarcinoma: somatic 0.61esophageal adenocarcinomaesophageal adenocarcinomaesophageal adenocarcinoma: somatic 0.61aneurysmal bone cystaneurysmal bone cystaneurysmal bone cyst: somatic 0.61gastric carcinomagastric carcinomagastric carcinoma: somatic 0.61exocrine pancreatic carcinomaexocrine pancreatic carcinomaexocrine pancreatic carcinoma: somatic 0.61lymphoid neoplasmlymphoid neoplasmlymphoid neoplasm: somatic 0.61skin squamous cell carcinomaskin squamous cell carcinomaskin squamous cell carcinoma: somatic 0.61breast ductal adenocarcinomabreast ductal adenocarcinomabreast ductal adenocarcinoma: somatic 0.61ovarian endometrioid adenocarcinoma wit…ovarian endometrioid adenocarcinoma with squamous differentiationovarian endometrioid adenocarcinoma with squamous differentiation: somatic 0.61kidney neoplasmkidney neoplasmkidney neoplasm: somatic 0.61hepatobiliary neoplasmhepatobiliary neoplasmhepatobiliary neoplasm: somatic 0.61bile duct carcinomabile duct carcinomabile duct carcinoma: somatic 0.61prostate adenocarcinomaprostate adenocarcinomaprostate adenocarcinoma: somatic 0.61carcinoma of liver and intrahepatic bil…carcinoma of liver and intrahepatic biliary tractcarcinoma of liver and intrahepatic biliary tract: somatic 0.61

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Antibody
GO CC high conf, UniProt loc med conf, UniProt SigP or TMHMM
PROTAC
Database Ubiquitination, Half-life Data

gnomAD loss of function constraint: o/e 0.16218000650405884 (upper bound 0.26844000816345215). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of CDH11's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of CDH11's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.